New applications of gemcitabine and future directions in the management of pancreatic cancer

Cancer ◽  
2002 ◽  
Vol 95 (S4) ◽  
pp. 941-945 ◽  
Author(s):  
James L. Abbruzzese
Keyword(s):  
Pancreatic Cancer ◽  
Future Directions ◽  
New Applications

Terpenoids as Potential Targeted Therapeutics of Pancreatic Cancer: Current Advances and Future Directions

2019 ◽  
pp. 111-116 ◽  
Author(s):  
Rama Rao Malla ◽  
Seema Kumari ◽  
K.G.K. Deepak ◽  
Murali Mohan Gavara ◽  
Shailender Guganavath ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Targeted Therapeutics ◽  
Future Directions

scholarly journals MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential

Genes ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 752 ◽  
Author(s):  
Rawat ◽  
Kadian ◽  
Gupta ◽  
Kumar ◽  
Chain ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Therapeutic Potential ◽  
Critical Role ◽  
Mirna Biogenesis ◽  
Effective Management ◽  
Future Directions ◽  
Novel Therapeutic Strategies ◽  
Conclusion Section

Pancreatic cancer is one of the most aggressive malignancies, accounting for more than 45,750 deaths annually in the U.S. alone. The aggressive nature and late diagnosis of pancreatic cancer, coupled with the limitations of existing chemotherapy, present the pressing need for the development of novel therapeutic strategies. Recent reports have demonstrated a critical role of microRNAs (miRNAs) in the initiation, progression, and metastasis of cancer. Furthermore, aberrant expressions of miRNAs have often been associated with the cause and consequence of pancreatic cancer, emphasizing the possible use of miRNAs in the effective management of pancreatic cancer patients. In this review, we provide a brief overview of miRNA biogenesis and its role in fundamental cellular process and miRNA studies in pancreatic cancer patients and animal models. Subsequent sections narrate the role of miRNA in, (i) cell cycle and proliferation; (ii) apoptosis; (iii) invasions and metastasis; and (iv) various cellular signaling pathways. We also describe the role of miRNA’s in pancreatic cancer; (i) diagnosis; (ii) prognosis and (iii) therapeutic intervention. Conclusion section describes the gist of review with future directions.

scholarly journals Strategies for in vitro engineering of the translation machinery

2019 ◽  
Vol 48 (3) ◽  
pp. 1068-1083 ◽  
Author(s):  
Michael J Hammerling ◽  
Antje Krüger ◽  
Michael C Jewett
Keyword(s):  
Chemical Biology ◽  
Protein Biosynthesis ◽  
Future Directions ◽  
Translation Machinery ◽  
Transfer Rnas ◽  
Translation Factors ◽  
Technological Advances ◽  
Translation Techniques ◽  
New Applications

Abstract Engineering the process of molecular translation, or protein biosynthesis, has emerged as a major opportunity in synthetic and chemical biology to generate novel biological insights and enable new applications (e.g. designer protein therapeutics). Here, we review methods for engineering the process of translation in vitro. We discuss the advantages and drawbacks of the two major strategies—purified and extract-based systems—and how they may be used to manipulate and study translation. Techniques to engineer each component of the translation machinery are covered in turn, including transfer RNAs, translation factors, and the ribosome. Finally, future directions and enabling technological advances for the field are discussed.

Hey Siri, tell me a story: Digital storytelling and AI authorship

2020 ◽  
Vol 26 (4) ◽  
pp. 808-823
Author(s):  
Sarah Thorne
Keyword(s):  
Artificial Intelligence ◽  
Language Processing ◽  
News Media ◽  
Future Directions ◽  
Daily Lives ◽  
Short Films ◽  
The Future ◽  
Commercial Applications ◽  
New Applications ◽  
Applications Of Ai

Surveying narrative applications of artificial intelligence in film, games and interactive fiction, this article imagines the future of artificial intelligence (AI) authorship and explores trends that seek to replace human authors with algorithmically generated narrative. While experimental works that draw on text generation and natural language processing have a rich history, this article focuses on commercial applications of AI narrative and looks to future applications of this technology. Video games have incorporated AI and procedural generation for many years, but more recently, new applications of this technology have emerged in other media. Director Oscar Sharp and artist Ross Goodwin, for example, generated significant media buzz about two short films that they produced which were written by their AI screenwriter. It’s No Game (2017), in particular, offers an apt commentary on the possibility of replacing striking screenwriters with AI authors. Increasingly, AI agents and virtual assistants like Siri, Cortana, Alexa and Google Assistant are incorporated into our daily lives. As concerns about their eavesdropping circulate in news media, it is clear that these companions are learning a lot about us, which raises concerns about how our data might be employed in the future. This article explores current applications of AI for storytelling and future directions of this technology to offer insight into issues that have and will continue to arise as AI storytelling advances.

scholarly journals Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Alessandro Bittoni ◽  
Matteo Santoni ◽  
Andrea Lanese ◽  
Chiara Pellei ◽  
Kalliopi Andrikou ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Case Series ◽  
Tumour Response ◽  
Tumour Regression ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Future Directions ◽  
Tumour Implantation

Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, being responsible for 6% of all cancer-related deaths. Surgical resection offers the only chance of cure, but only 15 to 20 percent of cases are potentially resectable at presentation. In recent years, increasing evidences support the use of neoadjuvant strategies in pancreatic cancer in patients with resectable pancreatic cancer as well as in patients with borderline resectable or locally advanced PDAC in order to allow early treatment of micrometastatic disease, tumour regression, and reduced risk of peritoneal tumour implantation during surgery. Furthermore, neoadjuvant treatment allows evaluation of tumour response and increases patient’s compliance. However, most evidences in this setting come from retrospective analysis or small case series and in many studies chemotherapy or chemoradiation therapies used were suboptimal. Currently, prospective randomized trials using the most active chemotherapy regimens available are trying to define the real benefit of neoadjuvant strategies compared to conventional adjuvant strategies. In this review, the authors examined available data on neoadjuvant treatment in patients with resectable pancreatic cancer as well as in patients with borderline resectable or locally advanced PDAC and the future directions in this peculiar setting.

Sign in / Sign up

Export Citation Format

Share Document